On Tuesday, Shares of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), added 3.52% and closed at $43.26 in the last trading session. TEVA stock opened its last trade at $42.01 and after floating in a range of $41.92 to $43.42. The company’s Market capitalization is $45.54 Billion with the total Outstanding Shares of 1.01 million. During the 52-week trading session the minimum price at which share price traded, registered at $41.67 and reached to max level of $66.55. The Earnings per Share of the company stands at $1.50. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) recently offered an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study in patients with chronic low back pain. Fasinumab is an investigational Nerve Growth Factor (NGF) antibody in clinical development for osteoarthritis pain and chronic low back pain.
Chronic Low Back Pain Program Update
The U.S. Food and Drug Administration (FDA) has placed the Phase 2b study in chronic low back pain on clinical hold and requested an amendment of the study protocol after observing a case of adjudicated arthropathy in a patient receiving high dose fasinumab who had advanced osteoarthritis at study entry. As a result of the FDA decision, Regeneron accomplished an unplanned interim review of results and has stopped dosing in the study. The unplanned analysis showed clear evidence of efficacy with improvement in pain scores in all fasinumab groups contrast to placebo at the 8- and 12-week time points (nominal p less than 0.01). Preliminary safety results are generally consistent with what has been formerly stated with the class. The Phase 2b chronic low back pain study enrolled about 70 percent of the targeted 800 patients in four dose groups: placebo, 6mg subcutaneously monthly, 9mg subcutaneously monthly and 9mg intravenously every two months. Regeneron has notified health authorities and study investigators about the decision. Patients will continue to be followed for up to 36 weeks.
Shares of JetBlue Airways Corporation (NASDAQ:JBLU), gained 0.06% and closed at $17.78 in the last trading session. JBLU stock opened its last trade at $17.89 and after floating in a range of $17.73 to $18.10. The company’s Market capitalization is $5.73 Billion with the total Outstanding Shares of 324.00 million. During the 52-week trading session the minimum price at which share price traded, registered at $17.73 and reached to max level of $18.10. The Earnings per Share of the company stands at $2.25. JetBlue Airways Corporation (JBLU) stated its preliminary traffic results for September 2016. Traffic in September raised 10.8 percent from September 2015, on a capacity increase of 7.9 percent.
Load factor for September 2016 was 83.2 percent, a boost of 2.1 points from September 2015. JetBlue’s preliminary completion factor was 99.5 percent and its on-time (1) performance was 78.7 percent. JetBlue’s preliminary revenue per available seat mile (RASM) for the month of September reduced about two percent year over year. For the third quarter of 2016, RASM is expected to decrease between three and four percent year over year, in line with prior expectations.